-Economic and Political Weekly The current regime seeks to reform labour laws with the understanding that these reforms will improve industrial growth and expand the possibilities of enterprise. However, there is already ample evidence from within India that this obsession with reforming labour law, particularly in the way the government has done it till now, will not take us any closer in creating more jobs or a healthy industrial sector. These...

-India Today Delhi attracts a bad name for its crime, traffic snarls and governance, but statistics generated by an international survey reveal that the national capital fares well in many ways when compared to other cities like London, New York, Tokyo, Istanbul and Berlin. Delhi's performance across a number of indicators was compared to these cities in terms of economy, population, society, governance, density, green space, environment and transport during the study...

-The Times of India Jagdish Bhagwati and Arvind Panagariya, hereafter BP, have argued for phasing out the National Rural Employment Guarantee Act in favour of cash transfers ("Rural Inefficiency Act", ToI, 23 October). It's surprising-and amusing-that two eminent economists have chosen to make a case based on prior beliefs and some sophomoric wordplay ('mis'leading economists), rather than on the available evidence. A survey by one of us of the empirical literature...

-The New York Times COPENHAGEN - The gathering risks of climate change are so profound that they could stall or even reverse generations of progress against poverty and hunger if greenhouse emissions continue at a runaway pace, according to a major new United Nations report. Despite growing efforts in many countries to tackle the problem, the global situation is becoming more acute as developing countries join the West in burning huge amounts...

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...